[go: up one dir, main page]

RS50373B - Čvrste lipidne smeše - Google Patents

Čvrste lipidne smeše

Info

Publication number
RS50373B
RS50373B YUP-136/02A YUP13602A RS50373B RS 50373 B RS50373 B RS 50373B YU P13602 A YUP13602 A YU P13602A RS 50373 B RS50373 B RS 50373B
Authority
RS
Serbia
Prior art keywords
solid lipid
lipid formulations
fatty acid
acid ester
tripalmitin
Prior art date
Application number
YUP-136/02A
Other languages
English (en)
Inventor
Christiaan DE SMIDT PASSCHIER
Paul Hadvary
Hans Lengsfeld
Hans Steffen
Joseph TARDIO
David MacFarland SMALL
Marcel SCHMID
Original Assignee
F. Hoffmann-La Roche Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50373(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag., filed Critical F. Hoffmann-La Roche Ag.,
Publication of YU13602A publication Critical patent/YU13602A/sh
Publication of RS50373B publication Critical patent/RS50373B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Farmaceutska smeša koja sadrži najmanje jedan inhibitor lipaza i najmanje jedan estar masne kiseline poliola, naznačena time što estar masne kiseline ima temperaturu topljenja >37°C a polioli su izabrani iz grupe koju čine glicerol, šećeri, derivati šećera i njihove smeše, i što smeša nije oblanda koja se sastoji od 5 g hitozana, 5 g maltodekstrina, 120 mg orlistata i 2 g tripalmitina. Prijava sadrži još 26 patentnih zahteva.
YUP-136/02A 1999-09-13 2000-09-11 Čvrste lipidne smeše RS50373B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99118179 1999-09-13

Publications (2)

Publication Number Publication Date
YU13602A YU13602A (sh) 2006-01-16
RS50373B true RS50373B (sr) 2009-11-10

Family

ID=8238989

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-136/02A RS50373B (sr) 1999-09-13 2000-09-11 Čvrste lipidne smeše

Country Status (36)

Country Link
US (1) US6703369B1 (sr)
EP (1) EP1216048B1 (sr)
JP (1) JP4217017B2 (sr)
KR (1) KR100523879B1 (sr)
CN (1) CN1197554C (sr)
AR (1) AR025609A1 (sr)
AT (1) ATE285783T1 (sr)
AU (1) AU769016B2 (sr)
BR (1) BRPI0013940B1 (sr)
CA (1) CA2383036C (sr)
CO (1) CO5210857A1 (sr)
CZ (1) CZ301844B6 (sr)
DE (1) DE60017156T2 (sr)
EG (1) EG24225A (sr)
ES (1) ES2233444T3 (sr)
GC (1) GC0000259A (sr)
HK (1) HK1049798B (sr)
HR (1) HRP20020206B1 (sr)
HU (1) HU229037B1 (sr)
IL (2) IL148570A0 (sr)
JO (1) JO2300B1 (sr)
MA (1) MA26817A1 (sr)
ME (1) ME00675B (sr)
MX (1) MXPA02002662A (sr)
MY (1) MY127430A (sr)
NO (1) NO328889B1 (sr)
NZ (1) NZ517396A (sr)
PE (1) PE20010661A1 (sr)
PL (1) PL199869B1 (sr)
PT (1) PT1216048E (sr)
RS (1) RS50373B (sr)
RU (1) RU2248218C2 (sr)
SI (1) SI1216048T1 (sr)
TR (1) TR200200605T2 (sr)
WO (1) WO2001019378A2 (sr)
ZA (1) ZA200201249B (sr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
KR100572785B1 (ko) * 2000-07-28 2006-04-19 에프. 호프만-라 로슈 아게 신규한 약학 조성물
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
DE10251963A1 (de) * 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Transmucosale pharmazeutische Darreichungsform
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
AU2003225649C1 (en) * 2003-03-04 2009-10-22 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
CA2582767C (en) * 2004-10-25 2011-05-24 Japan Tobacco Inc. Solid formulation with improved solubility and stability and method for producing said formulation
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
CA2626234A1 (en) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
KR100903504B1 (ko) * 2007-05-18 2009-06-17 강태용 비라칸사스 열매 추출물질을 포함하는 기능식품 및 체중 감소제
EP2076248A2 (en) * 2007-08-17 2009-07-08 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
ATE477820T1 (de) * 2007-09-12 2010-09-15 Mader S R L Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
EP2486805A1 (en) * 2011-02-11 2012-08-15 Puratos N.V. An emulsion whippable at room-temperature
PL2671455T3 (pl) * 2011-04-14 2017-10-31 J Oil Mills Inc Frakcjonowany olej palmowy oraz kompozycja oleju i produkt spożywczy ją zawierający
CN102552168B (zh) * 2012-01-31 2013-08-07 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
GB2501535A (en) 2012-04-26 2013-10-30 Sony Corp Chrominance Processing in High Efficiency Video Codecs
EA030444B1 (ru) * 2012-05-31 2018-08-31 Репрос Терапьютикс Инк. Способ лечения прогестеронзависимого состояния
WO2015063039A1 (en) 2013-10-28 2015-05-07 Nestec S.A. Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FR2710264B1 (fr) * 1993-09-21 1995-12-08 Rocher Yves Biolog Vegetale Utilisation pour le traitement des peaux mixtes d'une quantité efficace de substances actives.
AU5185398A (en) * 1996-12-04 1998-06-29 James S Pincott Process and apparatus for making crumb rubber from scrap tyres
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
NZ336755A (en) 1997-02-05 2001-06-29 F Use of gastrointestinal lipase inhibitors in particular tetrahydrolipstatin (orlistat)
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
WO2000009123A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
WO2000009122A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas

Also Published As

Publication number Publication date
ATE285783T1 (de) 2005-01-15
HRP20020206B1 (en) 2011-02-28
WO2001019378A3 (en) 2001-05-10
PL199869B1 (pl) 2008-11-28
ES2233444T3 (es) 2005-06-16
IL148570A (en) 2007-03-08
RU2248218C2 (ru) 2005-03-20
CN1373659A (zh) 2002-10-09
MXPA02002662A (es) 2002-07-30
PT1216048E (pt) 2005-04-29
AU7517700A (en) 2001-04-17
HK1049798A1 (en) 2003-05-30
PE20010661A1 (es) 2001-06-25
BRPI0013940B1 (pt) 2016-06-21
JP4217017B2 (ja) 2009-01-28
SI1216048T1 (en) 2005-06-30
EP1216048B1 (en) 2004-12-29
EP1216048A2 (en) 2002-06-26
HUP0202762A3 (en) 2005-04-28
HRP20020206A2 (en) 2004-04-30
DE60017156T2 (de) 2006-01-05
NO328889B1 (no) 2010-06-07
NO20021205D0 (no) 2002-03-12
CZ20021277A3 (cs) 2003-04-16
MA26817A1 (fr) 2004-12-20
BR0013940A (pt) 2002-05-14
EG24225A (en) 2008-11-10
AR025609A1 (es) 2002-12-04
TR200200605T2 (tr) 2002-08-21
US6703369B1 (en) 2004-03-09
MY127430A (en) 2006-11-30
PL356154A1 (en) 2004-06-14
MEP90908A (en) 2011-12-20
NO20021205L (no) 2002-03-12
JP2003509373A (ja) 2003-03-11
ZA200201249B (en) 2003-07-30
KR20020060177A (ko) 2002-07-16
AU769016B2 (en) 2004-01-15
DE60017156D1 (de) 2005-02-03
CA2383036A1 (en) 2001-03-22
RU2002107450A (ru) 2004-01-10
NZ517396A (en) 2003-10-31
HK1049798B (zh) 2005-08-05
WO2001019378A2 (en) 2001-03-22
IL148570A0 (en) 2002-09-12
CN1197554C (zh) 2005-04-20
CO5210857A1 (es) 2002-10-30
ME00675B (me) 2011-12-20
HUP0202762A2 (hu) 2003-01-28
JO2300B1 (en) 2005-09-12
CZ301844B6 (cs) 2010-07-07
HU229037B1 (en) 2013-07-29
KR100523879B1 (ko) 2005-10-26
YU13602A (sh) 2006-01-16
CA2383036C (en) 2006-01-10
GC0000259A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
RS50373B (sr) Čvrste lipidne smeše
DK1313510T3 (da) Injicerbar farmaceutisk sammensætning til systemisk administration af farmakologisk aktive aktivstoffer indeholdende middelkædede triglycerider
ATE215969T1 (de) Thermoplastisch verarbeitbare stärke bzw. stärkederivat-polymermischungen
DE69318503D1 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
RS50025B (sr) Farmaceutski preparati koji mogu da budu gelirani
HRP20010779B1 (en) Pharmaceutical composition
HUP0101653A3 (en) Fatty acid derivatives of bile acids and bile acid derivatives and pharmaceutical compositions thereof
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
ATE207346T1 (de) Orale pharmazeutische zusammensetzungen mit sexualhormonen
RS50035B (sr) Farmaceutska kompozicija koja sadrži fenofibrat i postupak za njeno dobijanje
HRP20010615B1 (en) Pharmaceutical compositions containing proton pump inhibitors
BR9610842A (pt) Composição farmacêutica compreendendo um inibidor de proteinase e um monoglicerídeo
KR950010875A (ko) 피부외용제
JO2324B1 (en) Pharmaceutical compounds for topical oral use
DE60031307D1 (de) Mikroverkapselte und mit gesteurter freigabe kräuter formulierungen
DK0657164T3 (da) Farmaceutiske præparater indeholdende staurosporinderivater og et polyalkylenglycolglycerid
AR016629A1 (es) Una solucion que comprende un azaesteroide farmaceuticamente activo y un ester de acido graso de glicerol o propilen glicol, composiciones farmaceuticasque comprenden la solucion y capsulas de gelatina rellenas con la composicion farmaceutica.
ECSP003653A (es) Formulaciones solidas de lipido
UY26337A1 (es) Formulaciones de lipidos solidos
KR950703333A (ko) 비이온계 계면활성제 함유 약학 조성물(Pharmaceutical Compositions Containing Nonionic Surfactants)
MX9307009A (es) Derivados de 5-[(imidaol{4,5-b}piridin-3-il]metil/benzofurano, procesopara su preparacion y composiciones farmaceuticas que los contienen.
KR900012613A (ko) 경구 투여용 의약조성물
WO2002049642A3 (en) Use of 5-hydroxy and 5-acyloxy-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acids and their esters as agents useful for healing skin lesions and stimulants of angiogenesis
IT9019494A0 (it) Derivati insaturi di acidi biliari, loro preparazione e composizione farmaceutiche che li contengono
SE9601483D0 (sv) Beredning av komposition